Lack of interaction between tolcapone and tolbutamide in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 5, 2000, Pages 544-551

  Jorga, Karin M ^a   Fotteler, Bärbel ^a   Gasser, Rodolfo ^a   Banken, Ludger ^a   Birnboeck, Herbert ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TOLBUTAMIDE; TOLCAPONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NORMAL HUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZOPHENONES; BLOOD GLUCOSE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUCOSE; HEADACHE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; MALE; NITROPHENOLS; SINGLE-BLIND METHOD; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0033669073     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009161     Document Type: Article

References (25)

1. Clinical potential of catechol-O-methyltransferase [COMT) inhibitors as adjuvants in Parkinson's disease
2. Remodelling the kinetics and dynamics of levodopa therapy in Parkinson's disease by inhibiting MAO-B with lazabemide and COMT with tolcapone
3. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
4. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans
5. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects
6. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
7. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in Parkinsonian patients
8. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline
9. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase
10. Tolbutamide hydroxylation by human liver microsomes: Kinetic charactensation and relationship to other cytochrome P-450 dependent xenobiotic oxidations
11. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
12. The relationship between the pharmacokinetic and pharmacodynamic effects of oral hypoglycaemic drugs
13. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly
14. Simultaneous determination of tolbutamide and its hydroxy and carboxy metabolites in plasma and urine by high-performance liquid chromatography
15. Co-regulation of phenytoin and tolbutamide metabolism in humans
16. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs
17. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients
18. The effect of cimetidine on tolbutamide kinetics
19. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers
20. A comparison of the two one-sided test procedures and the power approach for assessing the equivalence of average bioavailability
21. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P-450 2C9
22. Putative active site template model for cytochrome P-450 2C9 (tolbutamide hydroxylase)
23. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites